Global Gene Therapy Market & Pipeline Insight
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. With continuous growth in this market along with major research and developments breakthroughs, the global market opportunity for gene therapy is expected to reach USD 500 million by 2020.
There are only 2 gene therapies which have been approved till now. They are Gendicine and Rexin-G. While Gendicine is marketed in China, Rexin-G is marketed in Philippines. China, with its significant efforts in researching gene therapy has become the first country to approve gene therapy products across the globe in 2003. The growing need for developing an effective treatment for head-and-neck cancer, a condition more prevalent in China than in the west, sustained the interest among Chinese researchers in this area. The market for gene therapy is currently in the experimental stages. There has not been any success as yet in developing completely curative therapeutic drugs.
The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future.
Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. With continuous growth in this market along with major research and developments breakthroughs, the global market opportunity for gene therapy is expected to reach USD 500 million by 2020.
There are only 2 gene therapies which have been approved till now. They are Gendicine and Rexin-G. While Gendicine is marketed in China, Rexin-G is marketed in Philippines. China, with its significant efforts in researching gene therapy has become the first country to approve gene therapy products across the globe in 2003. The growing need for developing an effective treatment for head-and-neck cancer, a condition more prevalent in China than in the west, sustained the interest among Chinese researchers in this area. The market for gene therapy is currently in the experimental stages. There has not been any success as yet in developing completely curative therapeutic drugs.
The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future.
Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
- Gene Therapy Market Overview
- Significance of Gene Therapy in Cancer Therapeutics
- Current Applications of Gene Therapy to Cancer Treatment
- Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
- FDA & AMA Guidelines for Gene Therapy
- Gene Therapy Pipeline by Phase, Indications, Country & Company
- Gene Therapy Pipeline: 246 Drugs
- Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
- Cancer Gene Therapy Pipeline: 69 Drugs
1. INTRODUCTION TO GENE THERAPY
1.1 History of Gene Therapy
1.2 Vectors of Gene Therapy
1.2.1 Viral Vectors
1.2.2 Non-Viral Vectors
1.3 Gene Therapy Protocol
2. GENE THERAPY CLASSIFICATION
2.1 Somatic Gene Therapy
2.1.1 Technique of Somatic Gene Therapy
2.2 Germline Cell Therapy
2.2.1 Technique of Germiline Therapy
3. MECHANISM OF GENE THERAPY
3.1 Approach of Gene Therapy
3.2 Mechanism of Genetic Manipulation
4. GLOBAL GENE THERAPY MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Gene Therapy Clinical Pipeline Overview
4.3 Emerging Trends in Gene Therapy
5. SIGNIFICANCE OF GENE THERAPY IN CANCER THERAPEUTICS
6. CURRENT APPLICATIONS OF GENE THERAPY TO CANCER TREATMENT
6.1 Cancer Treatments Currently Available
6.2 Approaches to Cancer Gene Therapy
6.3 Gene Therapy Used in Cancer Treatment
6.4 Methods of Inserting Genes into Cancer Patients
6.5 Cancer Gene Therapy Clinical Insight
7. GLOBAL GENE THERAPY MARKET DYNAMICS
7.1 Favorable Parameters
7.1.1 Curing the Incurable Diseases
7.1.2 Testing Technology
7.1.3 Reimbursement Policy
7.1.4 Rising Incidence of Cancer
7.1.5 Increasing Investments
7.1.6 Integration of Bioinformatics
7.2 Growth Restraints
8. GENE THERAPY MARKET FUTURE GROWTH OUTLOOK
9. EMA GUIDELINES FOR GENE THERAPY
9.1 Non Clinical Testing for Inadvertent Germline Transmission of Gene Transfer Vectors
9.2 Scientific Requirements for the Environmental Risk Assessment of Gene Therapy Medicinal Products
9.3 Risk Based Approach Applied to Advanced Therapy Medicinal Products
9.4 Quality, Non Clinical & Clinical Aspects of Medicinal Products Containing Genetically Modified Cells
9.5 Follow Up of Patients Administered with Gene Therapy Medicinal Products
9.6 Non Clinical Studies Required Before First Clinical Use of Gene Therapy Medicinal Products
10. FDA GUIDELINES FOR GENE THERAPY
10.1 Preclinical Assessment of Investigational Cellular & Gene Therapy Products
10.2 Potency Tests for Cellular & Gene Therapy Products
10.3 Human Somatic Cell Therapy & Gene Therapy
10.4 Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events
11. GENE THERAPY PIPELINE BY PHASE, INDICATIONS, COUNTRY & COMPANY
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered
12. MARKETED GENE THERAPIES BY INDICATIONS, COUNTRY & COMPANY
12.1 Gendicine (Shenzhen SiBiono GeneTech)
12.2 Rexin-G (Epeius Biotechnologies)
13. SUSPENDED & DISCONTINUED GENE THERAPY IN PIPELINE
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended
14. COMPETITIVE LANDSCAPE
14.1 Advantagene
14.2 BioCancell
14.3 Celgene
14.4 Epeius Biotechnologies
14.5 GenVec
14.6 Genethon
14.7 Introgen Therapeutics
14.8 MultiVir
14.9 Shenzhen SiBiono GeneTech
14.10 Vical
14.11 ZIOPHARM Oncology
1.1 History of Gene Therapy
1.2 Vectors of Gene Therapy
1.2.1 Viral Vectors
1.2.2 Non-Viral Vectors
1.3 Gene Therapy Protocol
2. GENE THERAPY CLASSIFICATION
2.1 Somatic Gene Therapy
2.1.1 Technique of Somatic Gene Therapy
2.2 Germline Cell Therapy
2.2.1 Technique of Germiline Therapy
3. MECHANISM OF GENE THERAPY
3.1 Approach of Gene Therapy
3.2 Mechanism of Genetic Manipulation
4. GLOBAL GENE THERAPY MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Gene Therapy Clinical Pipeline Overview
4.3 Emerging Trends in Gene Therapy
5. SIGNIFICANCE OF GENE THERAPY IN CANCER THERAPEUTICS
6. CURRENT APPLICATIONS OF GENE THERAPY TO CANCER TREATMENT
6.1 Cancer Treatments Currently Available
6.2 Approaches to Cancer Gene Therapy
6.3 Gene Therapy Used in Cancer Treatment
6.4 Methods of Inserting Genes into Cancer Patients
6.5 Cancer Gene Therapy Clinical Insight
7. GLOBAL GENE THERAPY MARKET DYNAMICS
7.1 Favorable Parameters
7.1.1 Curing the Incurable Diseases
7.1.2 Testing Technology
7.1.3 Reimbursement Policy
7.1.4 Rising Incidence of Cancer
7.1.5 Increasing Investments
7.1.6 Integration of Bioinformatics
7.2 Growth Restraints
8. GENE THERAPY MARKET FUTURE GROWTH OUTLOOK
9. EMA GUIDELINES FOR GENE THERAPY
9.1 Non Clinical Testing for Inadvertent Germline Transmission of Gene Transfer Vectors
9.2 Scientific Requirements for the Environmental Risk Assessment of Gene Therapy Medicinal Products
9.3 Risk Based Approach Applied to Advanced Therapy Medicinal Products
9.4 Quality, Non Clinical & Clinical Aspects of Medicinal Products Containing Genetically Modified Cells
9.5 Follow Up of Patients Administered with Gene Therapy Medicinal Products
9.6 Non Clinical Studies Required Before First Clinical Use of Gene Therapy Medicinal Products
10. FDA GUIDELINES FOR GENE THERAPY
10.1 Preclinical Assessment of Investigational Cellular & Gene Therapy Products
10.2 Potency Tests for Cellular & Gene Therapy Products
10.3 Human Somatic Cell Therapy & Gene Therapy
10.4 Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events
11. GENE THERAPY PIPELINE BY PHASE, INDICATIONS, COUNTRY & COMPANY
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered
12. MARKETED GENE THERAPIES BY INDICATIONS, COUNTRY & COMPANY
12.1 Gendicine (Shenzhen SiBiono GeneTech)
12.2 Rexin-G (Epeius Biotechnologies)
13. SUSPENDED & DISCONTINUED GENE THERAPY IN PIPELINE
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended
14. COMPETITIVE LANDSCAPE
14.1 Advantagene
14.2 BioCancell
14.3 Celgene
14.4 Epeius Biotechnologies
14.5 GenVec
14.6 Genethon
14.7 Introgen Therapeutics
14.8 MultiVir
14.9 Shenzhen SiBiono GeneTech
14.10 Vical
14.11 ZIOPHARM Oncology
LIST OF TABLES AND FIGURES
Figure 1-1: Protocol for Human Gene Therapy Clinical Trials
Figure 2-1: Technique of Somatic Gene Therapy
Figure 2-2: Steps Involved in a Human Germline Gene Therapy Protocol
Figure 3-1: Genetic Modification of Organisms
Figure 4-1: Global Gene Therapy Market Opportunity (US$ Million), 2014-2020
Figure 4-2: Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-3: Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-4: No Development Reported in Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-5: No Development Reported in Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-6: Discontinued Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-7: Discontinued Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-8: Suspended Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-9: Suspended Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 6-1: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
Figure 6-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number), 2014
Figure 6-3: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-4: Suspended Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 6-5: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-6: Discontinued Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 6-7: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-8: No Development Reported Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 14-1: Advantagene Clinical Pipeline
Figure 14-2: Genethon Clinical Pipeline
Figure 14-3: MultiVir Clinical Pipeline
Figure 14-4: Vical Clinical Pipeline
Figure 14-5: ZIOPHARM Oncology Clinical Pipeline
Table 1-1: Approved Current Clinical Gene Therapy Protocols
Table 9-1: Classification of Integrating & Non-Integrating Vectors Based on the Parental Virus/Plasmid Characteristics
Table 9-2: Risk factors of GT Medicinal Products to be Considered
Table 10-1: Challenges to Potency Assay Development for CGT Products
Table 10-2: Commonly Used Gene Therapy Vectors in Clinical Trials
Figure 1-1: Protocol for Human Gene Therapy Clinical Trials
Figure 2-1: Technique of Somatic Gene Therapy
Figure 2-2: Steps Involved in a Human Germline Gene Therapy Protocol
Figure 3-1: Genetic Modification of Organisms
Figure 4-1: Global Gene Therapy Market Opportunity (US$ Million), 2014-2020
Figure 4-2: Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-3: Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-4: No Development Reported in Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-5: No Development Reported in Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-6: Discontinued Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-7: Discontinued Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-8: Suspended Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-9: Suspended Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 6-1: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
Figure 6-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number), 2014
Figure 6-3: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-4: Suspended Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 6-5: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-6: Discontinued Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 6-7: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-8: No Development Reported Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 14-1: Advantagene Clinical Pipeline
Figure 14-2: Genethon Clinical Pipeline
Figure 14-3: MultiVir Clinical Pipeline
Figure 14-4: Vical Clinical Pipeline
Figure 14-5: ZIOPHARM Oncology Clinical Pipeline
Table 1-1: Approved Current Clinical Gene Therapy Protocols
Table 9-1: Classification of Integrating & Non-Integrating Vectors Based on the Parental Virus/Plasmid Characteristics
Table 9-2: Risk factors of GT Medicinal Products to be Considered
Table 10-1: Challenges to Potency Assay Development for CGT Products
Table 10-2: Commonly Used Gene Therapy Vectors in Clinical Trials
